Invivoscribe’s IdentiClone Dx IGH won IVDR certification in the EU. Read what this means for clonality testing, lab adoption, and diagnostic competition.
QIAGEN wins FDA clearance for GI panels on QIAstat-Dx Rise. Discover what this means for syndromic testing platforms and molecular diagnostics adoption.
Insight Molecular Diagnostics advances GraftAssureDx toward FDA submission. Discover what this means for transplant rejection testing and dd-cfDNA diagnostics.
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.
Discover how Molecular Instruments’ ambient-temperature HCR Pro RNA-ISH on BOND-III could reshape clinical pathology automation and RNA diagnostics.
New England Biolabs launches an automation-ready cfDNA extraction kit. Find out what this changes for liquid biopsy workflows and diagnostics development.
Zepto Life Technology’s FungiFlex Mold Panel enables fast, noninvasive fungal diagnostics from blood. Find out what this could mean for patient care.
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
Fulgent Genetics acquires Bako Diagnostics and StrataDx to scale AI pathology, expand national reach, and advance precision medicine strategy. Read full analysis.